Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation.
Clément-Zhao A, Tanguy ML, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Savignoni A, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y. Clément-Zhao A, et al. Among authors: bontemps p. PLoS One. 2019 Aug 30;14(8):e0221816. doi: 10.1371/journal.pone.0221816. eCollection 2019. PLoS One. 2019. PMID: 31469859 Free PMC article.
Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study.
Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, de la Lande B, Baumann P, Missohou F, Lévy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Pernin V, Kirova Y. Dautruche A, et al. Among authors: bontemps p. Cancer Radiother. 2018 May;22(3):222-228. doi: 10.1016/j.canrad.2017.10.004. Epub 2018 Apr 9. Cancer Radiother. 2018. PMID: 29650388
Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.
Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Bollet M, Vago NA, Dendale R, Campana F, Fourquet A, Kirova YM. Pernin V, et al. Among authors: bontemps p. Br J Radiol. 2015 Apr;88(1048):20140800. doi: 10.1259/bjr.20140800. Epub 2015 Feb 3. Br J Radiol. 2015. PMID: 25645108 Free PMC article. Clinical Trial.
[Ductal carcinoma in situ: role of the boost].
Azria D, Auvray H, Barillot I, Baumann P, Benyoucef A, Bons-Rosset F, Bontemps P, Bourgier C, Breton-Callu C, Cowen D, Cretin J, Delalande B, Denis F, Ellis S, Gaci Z, Hannoun-Lévy JM, Hasbini A, Hennequin C, Lagrange JL, Lartigau E, Latorzeff I, Le Blanc-Onfroy M, Lecouillard I, Lemanski C, Levy C, Maingon P, Marchal C, Monnier A, Pradier O, Racadot S, Romestaing P, Serin D, Simon JM, Teyssier E, Tallet A, Tolédano A, Belkacémi Y. Azria D, et al. Among authors: bontemps p. Cancer Radiother. 2008 Nov;12(6-7):571-6. doi: 10.1016/j.canrad.2008.07.005. Epub 2008 Aug 13. Cancer Radiother. 2008. PMID: 18703372 Review. French.
[Rectal complications of radiotherapy].
Bosset JF, Bontemps P, Courvoisier P. Bosset JF, et al. Among authors: bontemps p. Cancer Radiother. 1997;1(6):775-7. doi: 10.1016/s1278-3218(97)82956-3. Cancer Radiother. 1997. PMID: 9614894 French.
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.
Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L. Horiot JC, et al. Among authors: bontemps p. Radiother Oncol. 1997 Aug;44(2):111-21. doi: 10.1016/s0167-8140(97)00079-0. Radiother Oncol. 1997. PMID: 9288839 Clinical Trial.
Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.
Lorgis V, Algros MP, Villanueva C, Chaigneau L, Thierry-Vuillemin A, Nguyen T, Demarchi M, Bazan F, Sautiere JL, Maisonnette-Lescot Y, Ringenbach F, Bontemps P, Pivot X. Lorgis V, et al. Among authors: bontemps p. Breast. 2011 Jun;20(3):284-7. doi: 10.1016/j.breast.2010.12.007. Epub 2011 Feb 1. Breast. 2011. PMID: 21288720 Free article.
Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases.
Benhmida S, Sun R, Gherga E, Hammoud Y, Rouvier J, Mauvais O, Bockel S, Louvrier A, Lebbad A, Bontemps P, Ortholan C, Bourhis J, Lestrade L, Sun XS. Benhmida S, et al. Among authors: bontemps p. Cancer Radiother. 2020 Dec;24(8):812-819. doi: 10.1016/j.canrad.2020.03.013. Epub 2020 Nov 2. Cancer Radiother. 2020. PMID: 33144061
[Hyperfractionated and accelerated radiotherapy in head and neck cancers: results of the EORTC trials and impact on clinical practice].
Horiot JC, Bontemps P, Begg AC, Le Fur R, Van den Bogaert W, Bolla M, N'Guyen T, Van den Weijngaert D, Bernier J, Lusinchi A, Stuschke D, Lopez Torrecilla D, Jancar B, Collette L, Van Glabbeke M, Pierart M. Horiot JC, et al. Among authors: bontemps p. Bull Cancer Radiother. 1996;83(4):314-20. Bull Cancer Radiother. 1996. PMID: 9081333 Clinical Trial. French. No abstract available.
27 results